SCHEMBL97041

SCHEMBL97041

OCCCOCCCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
LTA4H P09960 1/20 0.53
EPHX2 P34913 1/20 0.53
HRH3 Q9Y5N1 3/20 0.53
LMNA P02545 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.46
FFAR1 O14842 1/20 0.46
NPC1 O15118 1/20 0.46
RECQL P46063 1/20 0.46
RAB9A P51151 1/20 0.46
HDAC3 O15379 1/20 0.45
MAPK1 P28482 1/20 0.45
ADRA1A P35348 1/20 0.45
HDAC4 P56524 1/20 0.45
SLC6A3 Q01959 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10390390 0.98 IDO1 (0.53) IDO1MEN1KMT2ATDP1LTA4H
SCHEMBL2010505 0.94 TDP1 (0.52) IDO1MEN1KMT2ATDP1LTA4H
SCHEMBL26986089 0.94 IDO1 (0.53) IDO1MEN1KMT2ATDP1LTA4H
SCHEMBL10390214 0.92 TDP1 (0.50) IDO1MEN1KMT2ATDP1LTA4H
SCHEMBL1007405 0.92 IDO1 (0.52) IDO1MEN1KMT2ATDP1LTA4H
SCHEMBL3438759 0.92 IDO1 (0.52) IDO1MEN1KMT2ATDP1LTA4H
SCHEMBL1007629 0.92 IDO1 (0.52) IDO1MEN1KMT2ATDP1LTA4H
SCHEMBL6268788 0.92 TDP1 (0.54) IDO1MEN1KMT2ATDP1LTA4H
SCHEMBL10390505 0.92 IDO1 (0.55) IDO1MEN1KMT2ATDP1LTA4H
SCHEMBL97038 0.90 TDP1 (0.52) IDO1MEN1KMT2ATDP1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
EP-4551566-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2025-05-14 EP disclosed
CN-119816491-A New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2025-04-11 CN disclosed
WO-2024008941-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2024-01-11 WO disclosed
WO-2024008941-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2024-01-11 WO disclosed
EP-3565853-A1 PROCESS FOR MANUFACTURING POLYESTER RESINS Auriga Polymers, Inc. (US) 2019-11-13 EP disclosed
WO-2018128978-A1 PROCESS FOR MANUFACTURING POLYESTER RESINS AURIGA POLYMERS, INC. (US) 2018-07-12 WO disclosed
US-9464167-B2 Poly α-amino acid and ferroelectric memory element using same AJINOMOTO CO., INC. (JP) 2016-10-11 US disclosed
US-20140138654-A1 POLY ALPHA-AMINO ACID AND FERROELECTRIC MEMORY ELEMENT USING SAME AJINOMOTO CO., INC. (JP) 2014-05-22 US disclosed
EP-2709147-A1 POLY -AMINO ACID AND FERROELECTRIC MEMORY ELEMENT USING SAME Ajinomoto Co., Inc. (JP) 2014-03-19 EP disclosed
US-7964615-B2 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor ALMIRALL, S.A. (ES) 2011-06-21 US disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
US-20090042933-A1 Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed
US-5659065-A CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS NOVARTIS CORPORATION (US) 1997-08-19 US disclosed
EP-0678500-A1 Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors CIBA-GEIGY AG (CH) 1995-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB IDO1 2039/4885MEN1 4401/4885KMT2A 1059/4885
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX IDO1 4559/4885MEN1 4583/4885KMT2A 4742/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 IDO1 2948/4885MEN1 3912/4885KMT2A 2732/4885
US-20090042933-A1 Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor ADRB2, ADRA2C, ADRB1 IDO1 2032/4885MEN1 2839/4885KMT2A 1697/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 IDO1 2948/4885MEN1 3912/4885KMT2A 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.